GSK’s Mepolizumab: Benefit Of Going For Small Win
This article was originally published in The Pink Sheet Daily
Executive Summary
Company almost walked away from interleukin-5 monoclonal antibody before targeting severe asthma; one mistake of big pharma has been trying “to go for a big win,” CMO Stewart says.